An2 Therapeutics Inc (ANTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -18,213 | -10,028 | -35,174 | -26,464 | -17,111 |
| Depreciation Amortization | -175 | -81 | -1,070 | -953 | -742 |
| Accounts payable and accrued liabilities | -1,403 | -405 | -296 | -1,091 | -1,204 |
| Other Working Capital | -2,662 | -2,762 | -274 | -1,419 | -4,341 |
| Other Operating Activity | 3,382 | 1,203 | 6,980 | 5,329 | 5,175 |
| Operating Cash Flow | $-19,071 | $-12,073 | $-29,834 | $-24,598 | $-18,223 |
| Cash Flows From Investing Activities | |||||
| Purchase Of Investment | -16,363 | -2,703 | -46,189 | -37,863 | -33,973 |
| Sale Of Investment | 20,993 | 10,993 | 74,500 | 59,000 | 49,000 |
| Investing Cash Flow | $4,630 | $8,290 | $28,311 | $21,137 | $15,027 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 23,595 | 21,957 | 113 | 113 | 65 |
| Other Financing Activity | 15,223 | 15,372 | 0 | 0 | 0 |
| Financing Cash Flow | $38,818 | $37,329 | $113 | $113 | $65 |
| Beginning Cash Position | 19,941 | 19,941 | 21,351 | 21,351 | 21,351 |
| End Cash Position | 44,318 | 53,487 | 19,941 | 18,003 | 18,220 |
| Net Cash Flow | $24,377 | $33,546 | $-1,410 | $-3,348 | $-3,131 |
| Free Cash Flow | |||||
| Operating Cash Flow | -19,071 | -12,073 | -29,834 | -24,598 | -18,223 |
| Free Cash Flow | -19,071 | -12,073 | -29,834 | -24,598 | -18,223 |